Table of contents for Effects of veterinary medicines in the environment / editors, Mark Crane, Alistair B.A. Boxall, Katie Barrett.

Bibliographic record and links to related information available from the Library of Congress catalog.

Note: Contents data are machine generated based on pre-publication provided by the publisher. Contents may have variations from the printed book or be incomplete or contain other coding.


Counter
 
VM Table of Contents
Chapter 1: Introduction (9 p)
Mark Crane, Katie Barrett, and Alistair Boxall
Chapter 2: Use of Veterinary Medicines in the Environment (25 p)
Alistair Boxall, Mark Crane, Christian Corsing, Chuck Eirkson, and Alex Tait
2.1	Introduction
2.2	Veterinary medicine use
	2.2.1	Parasiticides
	2.2.2	Antibacterials
	2.2.3	Coccidiostats and antiprotozoals
	2.2.4	Antifungals
	2.2.5	Aquaculture medicines
	2.2.6	Hormones
2.3	Pathways to the environment
	2.3.1	Emissions during manufacturing and formulation
	2.3.2	Aquaculture
	2.3.3	Agriculture (livestock production)
	2.3.4	Companion/domestic animals
	2.3.5	Disposal of unwanted drugs
2. 4	Summary
2.5	References
Chapter 3: Environmental Risk Assessment and Management of Veterinary Medicines (71 p)
Joop de Knecht, Tatiana Boucard, Bryan Brooks, Mark Crane, Sarah Gerould, Jan Koschorreck, Gregor Scheef, Keith Solomon, and Zhixing Yan
3.1.	Introduction
3.2	Veterinary medicines in regulatory perspective 
	3.2.1	Legislation, scope and past guidelines for Environmental Risk Assessment (ERA) of veterinary medicines
		3.2.1.1	United States
		3.2.1.2	European Union
		3.2.1.3	Japan
		3.2.1.4	Australia
		3.2.1.5	Canada
	3.2.2	Current guidelines: VICH and VICH-EU-TGD
3.3	Refinement of VMP Risk Assessments
	3.3.1	Metabolism and Degradation
	3.3.2	Combination products
	3.3.3	Refinement of environmental exposure predictions
	3.3.4	Probabilistic Risk Assessment of Veterinary medicines
		3.3.4.1	Case study of a probabilistic risk assessment for dung fauna
3.4.	Risk Management 
	3.4.1	Risk mitigation measures within product authorization/ approval
	3.4.2	Risk assessment and management beyond authorization/approval
		3.4.2.1	The communication challenge 
		3.4.2.2	Incidence reporting and pharmacovigilance
			3.4.2.2.1	Reporting of an adverse event
			3.4.2.2.2	Validity of an adverse event
			3.4.2.2.3	Identifying environmental problems
			3.4.2.2.4	Incidence calculation
	3.4.3	Retrospective risk assessment
	3.4.4	Postmarket monitoring and remediation
		3.4.4.1	Monitoring endpoints
Chapter 4: Exposure Assessment of Veterinary Medicines in Aquatic Systems (72 p)
Chris Metcalfe, Alistair Boxall, Kathrin Fenner, Dana Kolpin, Mark Servos, Eric Silberhorn, and Jane Staveley
4.1.	Introduction
4.2.	Sources of veterinary medicines in the aquatic environment
	4.2.1.	Treatments used in agriculture
	4.2.2 	Treatments used in aquaculture
4.3.	Experimental studies into the entry, fate and transport of veterinary medicines in aquatic systems
	4.3.1	Aquatic exposure to veterinary medicines used to treat livestock
		4.3.1.1	Leaching to groundwater
		4.3.1.2	Movement to surface water
		4.3.1.3	Receiving waters
		4.3.1.4	Predicting exposure
		4.3.1.5	Comparison of modelled concentrations with measured concentrations
	4.3.2	Aquaculture treatments
		4.3.2.1	Inputs and fate of marine aquaculture treatments
		4.3.2.2	Freshwater Aquaculture
		4.3.2.3	Modelling exposure from aquaculture treatments
4.4	Conclusions
Chapter 5: Assessing the Aquatic Hazards of Veterinary Medicines (67 p)
Bryan W. Brooks, Gerald T. Ankley, James F. Hobson, James M. Lazorchak, Roger D. Meyerhoff, Keith R. Solomon
5.1	Introduction
5.2	Protection goals
5.3	Approaches to assess effects of veterinary medicines
	5.3.1	Current methods of assessing aquatic effects for risk assessment
		5.3.1.1	Lower tier approaches
		5.3.1.2	 Higher tier testing
		5.3.1.3	Limitations to current approaches
	5.3.2	Novel approaches to aquatic effects assessment
		5.3.2.1	Use of chemical characteristics, target organism efficacy data, toxicokinetic data and mammalian toxicology data
			5.3.2.1.1	Effects assessment
			5.3.2.1.2	Use of chemical characteristics and ADME data in assessment of bioaccumulation potential
		5.3.2.2	Use of ecotoxicogenomics in ecological effects assessment
5.4	Application Factors and Species Sensitivities 
5.5	Effects of veterinary medicines in the natural environment
	5.5.1	Episodic Exposures 
	5.5.2	Matrix effects 
	5.5.3	Metabolites and degradates 
	5.5.4	Mixtures
	5.5.5	Enantiomer specific hazard
	5.5.6	Sorption to sediment 
	5.5.7	Assessing effects on communities
5.6	Conclusions
5.7	References
Chapter 6: Exposure Assessment of Veterinary Medicines in Terrestrial Systems (51 p)
Louise Pope, Alistair Boxall, Christian Corsing, Bent Halling-Sørensen, Alex Tait, and Edward Topp 
6.1	Introduction
6.2	Absorption and excretion by animals
6.3	Fate during manure storage 
6.4	Releases to the environment
6.5	Factors affecting dissipation in the farm environment 
	6.5.1	Dissipation and transport in dung systems
	6.5.2	Dissipation and transport in soil systems
		6.5.2.1	Biotic degradation processes
		6.5.2.2	Abiotic degradation processes
		6.5.2.3	Sorption to soil
	6.5.3	Bound residues
6.6	Uptake by plants
6.7	Models for estimating the concentration of veterinary medicine in soil
	6.7.1	Intensively reared animals
	6.7.2	Pasture animals
	6.7.3	PEC refinement
6.8	Research needs
6.9	References 
Chapter 7: Assessing the Effects of Veterinary Medicines on the Terrestrial Environment (45 p)
Katie Barrett, Kevin Floate, John Jensen, Joe Robinson, Neil Tolson
7.1	Introduction
7.2	Considerations unique to veterinary medicines
	7.2.1	Routes of entry
	7.2.2	Additional safety data available in the dossier
	7.2.3	Residue data and detoxification by the target animal species
7.3	Protection Goals
7.4	Tiered Testing Strategy
7.5	Justification for existing testing methods
7.6	Use of indicator species
7.7	Short term/sub-lethal effects tests 
7.8	Tier A testing
	7.8.1	Physicochemical properties
	7.8.2	Fate 
	7.8.3	Microorganisms
	7.8.4	Plants
	7.8.5	Earthworms 
	7.8.6	Collembolans 
	7.8.7	Dung fauna
7.9	Tier B testing
7.10	Tier C testing
	7.10.1	Mesocosm and field testing
	7.10.2	Testing of Additional Species
	7.10.3	Monitoring Studies
7.11	Calculation of PNEC Concentrations and use of assessment factors
7.12	Metabolite Testing in Tier A and B
7.13	Secondary poisoning
7.14	Bound residues
7.15	Alternative endpoints
7.16	Modeling population and ecosystem effects, e.g., bio-indicator approaches
7.17	Research needs
7.18	References
Chapter 8: Workshop Conclusions and Recommendations (11 p)
Mark Crane, Katie Barrett, and Alistair Boxall
8.1	Workshop Conclusions
8.2	Workshop Recommendations

Library of Congress Subject Headings for this publication:

Veterinary drugs -- Environmental aspects.